Actinium Pharmaceuticals, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Actinium Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.14
1.03
0.08
0.09
Cost of revenue
0.9
Gross profit
0.24
Research and development
17.8
17.7
17.1
16.6
16.1
18
23.1
38.7
30
21.1
General and administrative
9.02
9.19
6.73
5.52
6.31
8.08
12
13.3
12.1
15.2
Operating expenses
26.8
26.9
23.8
22.1
22.4
26.1
35.1
52
42.1
36.3
Operating income
-26.8
-26.9
-23.8
-22.1
-22.4
-25
-34.1
-51.9
-42.1
-36.2
Interest expense
0.01
Interest income
3.1
3.88
2.36
Other non-operating income
2.53
0.31
0.17
0.17
0.18
0.19
1.09
3.1
3.88
2.36
Pre-tax income
-38.2
-33.3
Net income
-24.3
-26.6
-23.7
-21.9
-22.2
-24.8
-33
-48.8
-38.2
-33.9
EBITDA
-26.8
-26.9
-23.8
-21.7
-21.9
-24.4
-33.4
-51.7
-41.9
-36.1
EPS, basic
-14.67
-11.73
-6.45
-4.40
-1.83
-1.20
-1.37
-1.83
-1.27
-1.09
EPS, diluted
-14.67
-11.73
-6.45
-4.40
-1.83
-1.20
-1.37
-1.83
-1.27
-1.09
Shares, basic (weighted)
1.65
2.28
3.62
4.98
12.1
20.6
24.1
26.6
30.1
31.2
Shares, diluted (weighted)
1.65
2.28
3.62
4.98
12.1
20.6
24.1
26.6
30.1
31.2
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
20.5
17.4
13.7
9.25
63.6
77.8
109
76.7
72.9
48
Other current assets
1.84
0.44
0.62
0.79
1.32
1.48
0.07
0.23
0.36
0.17
Total current assets
22.4
17.8
14.3
10.1
64.9
79.7
111
78.3
74.5
49.4
Property, plant and equipment
0.09
0.06
0.12
0.11
0.31
0.34
0.6
0.55
0.36
0.3
Lease right-of-use assets
0.81
0.58
0.24
2.34
2.29
1.69
1.75
Goodwill
0.1
Total assets
22.5
18.3
14.9
11.7
66.4
80.4
114
81.4
76.9
51.8
Accounts payable
4.19
4.65
5.81
4.6
4.34
7.95
7.57
7.25
Deferred revenue
1
Total current liabilities
4.52
4.67
6.06
5.34
4.77
6.84
10.6
8.49
8.15
7.97
Long-term debt
0.9
Lease liabilities
2.08
1.55
0.98
0.97
Total liabilities
4.52
4.67
6.08
6.03
5.08
6.84
47.7
45.1
44.1
43.9
Total debt
0.02
0.9
Paid-in capital
155
177
196
214
292
329
355
374
409
418
Retained earnings
-137
-163
-187
-209
-231
-256
-289
-338
-376
-410
Other comprehensive income
-0.02
Shareholders' equity
18
13.7
8.81
5.64
61.3
73.5
66.5
36.4
32.8
7.83
Total equity
18
13.7
8.81
5.64
61.3
73.5
66.5
36.4
32.8
7.83
Total liabilities and equity
22.5
18.3
14.9
11.7
66.4
80.4
114
81.4
76.9
51.8
Shares outstanding
1.9
2.73
3.94
5.49
17.5
22.1
25.7
27.6
31.2
31.2
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-24.3
-26.6
-23.7
-21.9
-22.2
-24.8
-33
-48.8
-38.2
-33.9
Depreciation and amortization
0.08
0.06
0.05
0.42
0.45
0.52
0.7
0.21
0.2
0.17
Stock-based compensation
4.3
3.49
1.8
1.3
1.25
1.69
2.8
3.84
5.29
9.19
Deferred income tax
13.8
Change in payables
2.72
0.41
1.13
-1.26
-0.26
1.2
4.6
-2.18
-0.39
-0.35
Cash from operations
-20.8
-21.6
-20.6
-21.5
-21.6
-20.9
8.64
-47.3
-33.1
-24.6
Capital expenditures
-0.06
-0.02
-0.1
-0.06
-0.25
-0.13
-0.37
-0.15
-0.01
-0.1
Purchases of investments
-0.05
Cash from investing
-0.11
-0.02
-0.1
-0.06
-0.25
-0.13
-0.37
-0.15
-0.01
-0.1
Stock issued
16
18.8
17
15.9
76.6
35.3
23.2
14.6
29.3
Cash from financing
15.8
18.8
17
17.1
76.2
35.2
23.1
14.9
29.3
-0.22
Exchange rate effect
0.01
Net change in cash
-5.12
-2.76
-3.69
-4.41
54.3
14.2
31.4
-32.6
-3.76
-24.9
Free cash flow
-20.8
-21.6
-20.7
-21.5
-21.9
-21
8.28
-47.5
-33.1
-24.7
Interest paid
0.01
0.03
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.58 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
37.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
28.2%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
-55.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-76.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-51.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-33.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-32.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-23.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-4.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
8.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
20.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.08x
Current assets / current liabilities.
Quick ratio
3.94x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.94x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.72
Cash from operations / diluted weighted shares.
Book value per share
$0.96
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
4.39x
Market cap / net income. Only when net income is positive.
P/B
1.64x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.64x
Market cap / tangible book value, when positive.
EV/EBIT
1.38x
Enterprise value / operating income, when both are positive.
EV/EBITDA
1.35x
Enterprise value / EBITDA, when both are positive.
Earnings yield
22.8%
Net income / market cap (the inverse of P/E).
What was Actinium Pharmaceuticals, Inc.'s revenue in fiscal 2025?
Actinium Pharmaceuticals, Inc. reported revenue of $90.0K for fiscal 2025.
Was Actinium Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $33.9M.
How much free cash flow did Actinium Pharmaceuticals, Inc. generate in fiscal 2025?
Cash from operations of $24.6M minus capital expenditures of $104.0K left free cash flow of -$24.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.